On 16 April 2026 the FDA removed BPC-157 and 11 other peptides from Category 2, and a Pharmacy Compounding Advisory Committee (PCAC) hearing on 23 and 24 July 2026 is now reviewing whether to add BPC-157, alongside TB-500, KPV, MOTS-C, DSIP, Semax and Epitalon, to the 503A "positive bulks list" (see our FDA PCAC July 2026 explainer)
Despite the issues and challenges summarized above, we should take full advantage of nanotechnology and overcome these hurdles
Oxidative stress is an imbalance between free radicals (unstable molecules that can damage cells) and the antioxidants that neutralize them
If we can boost the activity of anti-oxidant genes that help stave off this damage, then we should be able to delay the deterioration of our tissues and our DNA, thus extending longevity
(2) Exploring predictors as early as possible after admission where patient could recover and will need a transplant to survive